MedTrace Logo

Serological Testing for COVID-19 (SARS-CoV-2) in ESKD

NCT04378686 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2024-07-03

No results posted yet for this study

Summary

Starting in late 2019, the world is facing a pandemic with the SARS-CoV-2 virus. Patients with end-stage kidney disease and on treatment with renal replacement therapy are high risk patients, as they are unable to maximize social distancing.

We plan to gather epidemiological data using two different diagnostic approaches. We will compare a symptom-driven screening, in combination with a nasopharyngeal swab plus computed tomography (clinical approach) against serological surveillance.

Conditions

  • SARS-CoV 2
  • End Stage Renal Failure on Dialysis

Interventions

OTHER

dialysis

treatment with dialysis. This can be hemodialysis, hemodiafiltration, peritoneal dialysis

Sponsors & Collaborators

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Principal Investigators

  • Bjorn Meijers, MD, PhD · UZ Leuven

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-23
Primary Completion
2022-12-12
Completion
2022-12-12

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04378686 on ClinicalTrials.gov